DOCSLIB.ORG

Essential Drugs List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Essential Drugs List ESSENTIAL DRUGS LIST ﺃ- ﺍﻻﺴﺒﻘﻴﺔ ﺍﻻﻭﻟﻰ (priority 1):- ﻭﺘﺸﺘﻤل ﻋﻠﻰ ﻤﺠﺎﻤﻴﻊ ﺍﻻﺩﻭﻴﺔ ﺍﻟﻀﺭﻭﺭﻴﺔ ﺍﻟﻤﻌﺭﻭﻓﺔ ﺒﺎﻟﻔﻌﺎﻟﻴﺔ ﺍﻟﻌﺎﻟﻴﺔ ﻭﺴﻼﻤﺔ ﺍﺴﺘﻌﻤﺎﻟﻬﺎ ﻭﺘﻘﺴﻡ ﺍﻟﻰ:- A ---- Drugs of First choice ﺍ ﻭ ﻻﹰ:- ﻤﺠﻤﻭﻋﺔ ﺍﺩﻭﻴﺔ ﺍﻻﺨﺘﻴﺎﺭ ﺍﻻﻭل ﻭﻤﺅﺸﺭ A/a ---- Alternative drugs ﺜ ﺎ ﻨ ﻴ ﺎﹰ:- ﻤﺠﻤﻭﻋﺔ ﺍﺩﻭﻴﺔ ﺍﻻﺨﺘﻴـﺎﺭ ﺍﻻ ﻭل ﻤـﻥ ﺍﻟﺒـﺩﺍﺌل ﻤـﻥ ﻨﻔـﺱ ﺍﻟﻤﺠﻤﻭﻋﺔ A/L---- Essential but of limited use ﺜ ﺎ ﻟ ﺜ ﺎﹰ:- ﻤﺠﻤﻭﻋﺔ ﺍﺩﻭﻴﺔ ﺍﻟﺨﻁ ﺍﻻﻭل ﻤﺤﺩﻭﺩﺓ ﺍﻻﺴﺘﻌﻤﺎل This category represent the most necessary drugs that should be regularly available in adequet quantities to satisfy the needs of the majority of Iraqi people and should be of a good quality to ensure safety and efficacy. ﺏ- ﺍﻻﺴﺒﻘﻴﺔ ﺍﻟﺜﺎﻨﻴﺔ (priority 2):- ﻭﺘﺸﺘﻤل ﻋﻠﻰ ﺍﻻﺩﻭﻴﺔ ﺍﻟﻤﻌﺭﻭﻓﺔ ﺒﻔﻌﺎﻟﻴﺘﻬﺎ ﺍﻟﻌﺎﻟﻴﺔ ﻭﺴﻼﻤﺔ ﺍﻻﺴﺘﻌﻤﺎل ﻤﻊ ﺨﺼﺎﺌﺹ ﻭﻤﻭﺍﺼﻔﺎﺕ ﺍﻀﺎﻓﻴﺔ ﻭﻟﻜﻨﻬﺎ ﺒﺎﻫﻀﺔ ﺍﻟﺜﻤﻥ ﻟﺫ ﻟﻙ ﺘﻭﻓﺭ ﺤ ﺎ ﻟ ﻴ ﺎﹰ ﺒﻜﻤﻴﺎﺕ ﻤﺤـﺩﻭﺩﺓ ﻭﺘـﻭﺯﻉ ﻋﻠﻰ ﺍﻟﻤﺭﺍﻜﺯ ﺍﻟﺘﺨﺼﺼﻴﺔ ﺍﻭ ﺘﻭﺼﻑ ﻟﻠﻤﺭﻴﺽ ﺍﻟﺫﻱ ﻟﻡ ﻴﺴﺘﺠﺏ ﻻﺩﻭﻴﺔ ﺍﻻﺴﺒﻘﻴﺔ ﺍﻻﻭﻟـﻰ ﺍﻭ ﻟﻌـﺩﻡ ﻤﻼﺌﻤﺘﻬﺎ ﺒﺴﺒﺏ ﺍﻻﺜﺎﺭ ﺍﻟﺠﺎﻨﺒﻴﺔ ﺍﻭ ﻟﻠﺤﺎﻻﺕ ﺍﻟﻤﺭﻀﻴﺔ ﺍﻟﻤﺼﺤﻭﺒﺔ ﺒﺎﻻﺨﺘﻼﻁـﺎﺕ ﺍﻟﻤﻌﻘـﺩﺓ ، ﻭﺘﻘـﺴﻡ ﻭﺘﺅﺸﺭ ﻫﺫﻩ ﺍﻻﺴﺒﻘﻴﺔ ﻜﻤﺎ ﻓﻲ (ﺃ) : B ---- First choice ﺃ ﻭ ﻻﹰ:- ﺩﻭﺍﺀ ﺍﻟﺨﻴﺎﺭ ﺍﻻﻭل B/a ---- Alternative ﺜ ﺎ ﻨ ﻴ ﺎﹰ:- ﺩﻭﺍﺀ ﺍﻟﺨﻴﺎﺭ ﺍﻻﻭل ﻤﻥ ﺍﻟﺒﺩﺍﺌل ﻤﻥ ﻨﻔﺱ ﺍﻟﻤﺠﻤﻭﻋﺔ B/L ---- Limited use ﺜ ﺎ ﻟ ﺜ ﺎﹰ:- ﺩﻭﺍﺀ ﺍﻟﺨﻴﺎﺭ ﺍﻻﻭل ﻤﺤﺩﻭﺩ ﺍﻻﺴﺘﻌﻤﺎل ﺠـ- ﺍﻻﺴﺒﻘﻴﺔ ﺍﻟﺜﺎﻟﺜﺔ (priority 3):- ﻭﺘﺸﻤل ﺍﻻﺩﻭﻴﺔ ﺍﻟﻤﻜﻤﻠﺔ ﺍﻟﻤﺘﺒﻘﻴـﺔ ﻤـﻥ ﻗﺎﺌﻤـﺔ ﺍﻻ ﺩﻭﻴـﺔ ﺍﻻﺴﺎﺴـﻴﺔ Complimantary drugs ﻭﺘﺅﺸﺭ ﻜﻤﺎ ﻴﻠﻲ:- C ---- ﺃ ﻭ ﻻﹰ:- ﺍﺩﻭﻴﺔ ﺍﻟﺨﻴﺎﺭ ﺍﻻﻭل ﻤﻥ ﺍﻻﺴﺒﻘﻴﺔ ﺍﻟﺜﺎﻟﺜﺔ C/a ---- Alternative ﺜ ﺎ ﻨ ﻴ ﺎﹰ:- ﺍﺩﻭﻴﺔ ﺍﻟﺨﻴﺎﺭ ﺍﻻﻭل ﻤﻥ ﺍﻟﺒﺩﺍﺌل ﻤﻥ ﺍﻻﺴﺒﻘﻴﺔ ﺍﻟﺜﺎﻟﺜﺔ C/L ---- Limited use ﺜ ﺎ ﻟ ﺜ ﺎﹰ:- ﺍﺩﻭﻴﺔ ﺍﻟﺨﻴﺎﺭ ﺍﻻﻭل ﻤﺤﺩﻭﺩ ﺍﻻﺴﺘﻌﻤﺎل ﻤﻥ ﺍﺩﻭﻴﺔ ﺍﻻﺴﺒﻘﻴﺔ ﺍﻟﺜﺎﻟﺜﺔ ﻟﺴﻬﻭﻟﺔ ﺍﻟﺘﻭﻀﻴﺢ:- A : Drugs of first choice (Reasonable cost). A/a: First choice alternative drugs. A/L: First choice drugs of limited use. B: First choice drugs (Best & expensive) B/a: First choice alternative drugs. B/L: First choice drugs of limited use. C: Complementary drugs. Decision : All human products must be of human recombinant origin wherever these are avialable in the markets. : For oral solution it is preferable: Syrup then Suspension and then Elixir : Caution To be written if the products contian metabisulphite as following (Caution: this product contain metabisulphite – may cause broncho spasm in atopic & Asthmatic subjects) : There is no objection of all tablets that approved in the national list as scored tab to be plain tab (Not scored) ESSENTIAL DRUGS LIST & THE MOST NECESSARY DRUGS 1 CARDIOVASCULAR SYSTEM 1 A Positive inotropic drugs 1 Aa Digitalis glycoside B Digoxin tab 125 mcg A Digoxin scored tab 250 mcg A Digoxin PG Elixir 50mcg /ml (60ml) A Digoxin inj 250 mcg/ml, ( 2ml Amp) 1 A.b Phosphodiesterase inhibitors: A/L Enoximone inj:5mg/ml (20ml Amp) Only For heart specilised centers – See section 17 1 B Diuretics A/L Bumetanide tab 1 mg B Chlorthalidone tab 50mg A Frusemide I.V. , I.M. inj 20mg/2ml Amp A Frusemide I.V. infusion inj 10mg/ml, ( 25ml - Amp) A Frusemide tab 40mg A Frusemide oral solution pead. Liquid 1mg/1ml A Frusemide oral solution 4mg/ml A Hydrochlorothiazide tab 25mg A Hydrochlorothiazide tab scored 50mg B/L Indapamide tab 2.5mg A Mannitol 10% I.V. infusion 500ml A Mannitol 20% I.V. infusion 500ml B/L Metolazone tab 5mg A Spironolactone tab 25mg Spironolactone tab 50mg (558) A Spironolactone tab 100mg 1 C Beta adrenoceptor blocking drugs A Atenolol tab 100mg A Atenolol tab (or scored tab) 50mg A Atenolol inj 500mcg/ml (10ml Amp) A/L/a Bisoprolol fumarate scored tab 5mg A/L Carvedilol 3.125mg tab A/L Carvedilol 6.25mg tab A/L Carvedilol 25mg tab 1 اﻟﻬﻴﺌﺔ اﻟﻮﻃﻨﻴﺔ ﻻﻧﺘﻘﺎء اﻻدوﻳﺔ National Board For Selection Of The Drugs/ NBSD B/L Esmolol Hcl I.V. infusion 10mg /ml (10ml vial) (CCU) A/L Labetalol inj 5mg/ml, (20ml Amp) B/L Labetalol tab 200mg A/a Metoprolol tartrate tab 50mg A/a Metoprolol tartrate 100mg tab A/a Metoprolol tartrate I.V. inj. 1mg /1ml (5ml Amp) C/L Pindolol tab 5mg A/L Propranolol Hcl slow I.V. inj 1mg/ml (1ml -Amp) A Propranolol Hcl tab 10mg A Propranolol Hcl tab (or scord tab) 40mg 1 D Anti arrhythmic drugs A Adenosine inj. 3mg/ml (2ml – vial) or amp. A/L Amiodarone Hcl inj 50mg/ml ( 3ml - Amp) A Amiodarone Hcl tab 200mg A/L Disopyramide caps 100mg B/L Disopyramide tab Retard (s/r) 250mg A/L Disopyramide inj 10mg/ml (5ml- Amp) (Hospital only) A/L Flecainide acetate 50mg Tab. (Only in the heart specialised center) A/L Flecainide acetate inj 10mg/ ml (15ml-amp) (Only in the heart specialized center) A Lignocaine Hcl 2% 20mg /ml 2ml – amp ( CCU) A/L Mexiletine Hcl caps 200mg A/L Mexiletine Hcl I.V., I.V. infusion inj 25mg/ml, (10ml Amp) A/L/a Procainamide Hcl slow I.V., I.V. infusion inj 100mg/ml, (10ml vial) A/L/a Procainamide Hcl tab 500mg A Propafenon Hcl tab 150mg C Quinidine sulphate tab 200mg A Verapamil Hcl inj 2.5mg/ml, (2ml Amp) A Verapamil Hcl tab 40mg A Verapamil Hcl tab 80mg 1 E Anti - hypertensive drugs Note:- Principles for ARBs group (Angioteusin II Receptor blockers) To be available & dispensed limitly for the following cases only:- 1- Mild to moderately severe heart failure. 2- Diabetic (Type I & type II) Nephropathy with or with out hypertension (H.T) i-e D.M. concomitant with H.T or with out, that effecting on kidney’s function by the following evidences: a- Micro & macro albumin urea. b- Reduced GFR. c- Elevated serum creatinin. 3- Hypertension with proteinuria. When ACE-Is not tolerated by patient (e.g: side effects) Such as coughing/ or decrement in anti- proteinuric activity of ACEIs in those patients. Provided that (ARBs) to be dispensed by aspecialist or consultant in internal medicine , documented by report of scientific proofs & tests which referring to those above mentioned cases (a, b, c). There fore, ARBs as agroup of ACEIs not given or used by pregnant wowen at all. A Captopril tab 25mg A Captopril tab 50mg A Candesartan cilexetil scored tab 8mg (can be imported if irbesartan ,telmisartan, valsartan , Losartan are not avialable) (566) A Candesartan cilexetil 16mg tab (can be imported if irbesartan ,telmisartan, valsartan , Losartan are not avialable) (566) A/a Doxazosin mesylate equivalent to doxazosine 2mg scored tab A/a Enalapril maleate scored tab 5mg 2 اﻟﻬﻴﺌﺔ اﻟﻮﻃﻨﻴﺔ ﻻﻧﺘﻘﺎء اﻻدوﻳﺔ National Board For Selection Of The Drugs/ NBSD A/a Enalapril maleate scored tab 10mg A/a Enalapril maleate scored tab 20mg A/L Hydralazine Hcl I.V. Infusion inj 20mg per Amp. B Hydralazine Hcl tab 25mg (limited use) A Irbesartan 150mg tab (can be imported if candesartan ,telmisartan, valsartan , Losartan are not avialable) (566) A Irbesartan 300mg tab (can be imported if candesartan , valsartan , Losartan are not avialable) (566) A/a Lisinopril (Lisinopril (as base) or Lisinopril (anhydrous) , Lisinopril (as dihydrate) , the same drug with or without water of hydration) tab 10mg A/a Lisinopril (Lisinopril (as base) or Lisinopril (anhydrous) , Lisinopril (as dihydrate) , the same drug with or without water of hydration) tab 20mg A Losartan potassium tab 50mg (can be imported if, candesartan , irbesartan,telmisartan, valsartan are not avialable) A/L Methyldopate inj 50mg/ml (5ml Amp) (limited use) A Methyldopa tab 250mg B/L Minoxidil tab 5mg (limited) A/L Phenoxybenzamine Hcl caps 10mg A/L Phentolamine mesylate inj 10mg/ml (1ml Amp) C Prazosin Hcl tab or scord tab 1mg A/L Ramipril 2.5 mg tab. (598) A/L Ramipril 5 mg tab. (598) A/L Ramipril 10 mg tab. (598) A/L Sodium nitroprusside I.V. infusion 50mg Amp or vial with solvent A Terazosin as Hcl tab 2mg A Terazosin as Hcl tab 5mg A/L Tolazoline Hcl inj I.V. (limited use for cardiac surgery) A/a Telmisartan Tab 40mg (can be imported if, irbesartan, candesartan , valsartan , Losartan are not avialable) (566) A/a Telmisartan Tab 80mg (can be imported if , irbesartan , candesartan , valsartan , Losartan are not avialable) (566) A Valsartan tab or cap 80mg (can be imported if , irbesartan , candesartan , Losartan, telmisartan are not avialable) (678) A Valsartan tab or cap 160mg (can be imported if , irbesartan , candesartan , Losartan, telmisartan are not avialable) (678) 1 F Vasodilators A/a Amlodipine (as besylate) tab 2.5mg A/a Amlodipine (as besylate) scored tab 5mg or Cap. A Diltiazem HCl tab or cap 60mg (normal release) A Diltiazem HCl tab or cap (s/r) 90mg B Diltiazem HCl tab or cap (s/r) 120mg B Diltiazem HCl I.V inj or infusion 25mg/vial A Glyceryl trinitrate ( sublingual) tab 0.5mg A/L Glyceryl trinitrate inj 5mg/1ml Amp (5 ml-Amp) B Glyceryl trinitrate Patches 10mg B Glyceryl trinitrate Patches 5mg B Glyceryl trinitrate Patches 25mg A Isosorbide dinitrate tab (s/l i-e sublingual)5mg A Isosorbide dinitrate tab 10mg B Isosorbide dinitrate tab (s/r) 20mg or retard cap 20mg A/a Isosorbide mononitrate tab 10mg A Nifedipine (s/r) caps or tab. 10mg (40% of the need) A Nifedipine cap or tab (s/r or retard) 20mg (60% of the need) A/L Nimodipine tab 30mg 3 اﻟﻬﻴﺌﺔ اﻟﻮﻃﻨﻴﺔ ﻻﻧﺘﻘﺎء اﻻدوﻳﺔ National Board For Selection Of The Drugs/ NBSD A/L Nimodipine I.V. infusion 200mcg/ml (50ml vial) B Oxpentifylline tab 400mg (Pentoxifylline) 1 G Sympathomimetic drugs A Dobutamine (as Hcl) I.V infusion inj 250mg/amp or vial (12.5mg/ml 20ml amp or vial). A Dopamine Hcl inj 40mg/ml, (5ml Amp) A/L Ephedrine Hcl inj 3% 30 mg / ml,( 1ml Amp) ( hypotension prevention in epidural/spinal anaesthesia) A/a Ephedrine Hcl inj 3mg / ml, 10 ml Amp A/L Metaraminol (as tartrate) inj 10mg/ml, (1ml Amp) A/L Phenylephrine Hcl inj 10mg/ml, (1ml Amp) By s.c.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • National Code Item Name 1
    NATIONAL CODE ITEM NAME 1 CARDIOVASCULAR SYSTEM 1A Positive inotropic drugs 1AA Digtalis glycoside 02-01-00001 Digoxin 62.5mcg Tablet 800,000 02-01-00002 Digitoxin 100mcg Tablet 800,000 02-01-00003 Digoxin 125 mcg Tablet 800,000 02-01-00004 Digoxin 250 mcg Tablet 15,000,000 02-01-00005 Digoxin 50mcg /ml PG Elixir 800,000 02-01-00006 Digoxin 250 mcg/ml inj (2ml) Ampoule 800,000 1AB PHOSPHODIESTERASE INHIBITORS 02-01-00007 Enoximone 5mg/1ml inj (20ml) Ampoule 800,000 1B DIURETICS 02-01-00008 Amiloride Hcl 5mg + Hydrochlorthiazide 50mg Tablet 50,000,000 02-01-00009 Bumetanide 1 mg Tablet 800,000 02-01-00010 Chlorthalidone 50mg Tablet 2,867,000 02-01-00011 Ethacrynic acid 50mg as sodium salt inj (powder for reconstitution) Vial 800,000 02-01-00012 Frusemide 20mg/2ml inj Ampoule 6,625,000 02-01-00013 Frusemide 10mg/ml,I.V.infusion inj (25ml) Ampoule 800,000 02-01-00014 Frusemide 40mg Tablet 20,000,000 02-01-00015 Frusemide 500mg Scored Tablet 800,000 02-01-00016 Frusemide 1mg/1ml Oral solution peadiatric Liquid 800,000 02-01-00017 Frusemide 4mg/ml Oral Solution 800,000 02-01-00018 Frusemide 8mg/ml oral Solution 800,000 02-01-00019 Hydrochlorothiazide 25mg Tablet 800,000 02-01-00020 Hydrochlorothiazide 50mg Tablet 950,000 02-01-00021 Indapamide 2.5mg Tablet 800,000 02-01-00022 Indapamide 1.5mg S/R Coated Tablet 800,000 02-01-00023 Spironolactone 25mg Tablet 7,902,000 02-01-00024 Spironolactone 100mg Tablet 11,451,000 02-01-00025 Xipamide 20mg Tablet 800,000 1C BETA-ADRENOCEPTER BLOCKING DRUGS 02-01-00026 Acebutolol 100mg Tablet 800,000 02-01-00027 Acebutolol 200mg Tablet 800,000 02-01-00028 Atenolol 100mg Tablet 120,000,000 02-01-00029 Atenolol 50mg Tablet or (scored tab) 20,000,000 02-01-00030 Atenolol 25mg Tablet 1,483,000 02-01-00031 Bisoprolol fumarate 5mg Scored Tablet 800,000 02-01-00032 Bisoprolol fumarate 10mg Scored Tablet 800,000 02-01-00033 Carvedilol 6.25mg Tablet 800,000 02-01-00034 Carvedilol 12.5mg Tablet 800,000 02-01-00035 Carvedilol 25mg Tablet 800,000 02-01-00036 Esmolol Hcl 10mg/ml I.V.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Chromatographic Methods for Simultaneous Determination of Diiodohydroxyquinoline and Metronidazole in Their Binary Mixture
    Chromatographic methods for simultaneous determination of diiodohydroxyquinoline and Metronidazole in their binary mixture Nouruddin Wageih Ali1*, Mohammed Gamal1 and Mohammed Abdelkawy2 1Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Alshaheed Shehata Ahmed Hegazy St., Beni-Suef Egypt 2Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo, Egypt Abstract: Two chromatographic methods were developed for analysis ofdiiodohydroxyquinoline (DIHQ) and metronidazole (MTN). In the first method, diiodohydroxyquinoline and metronidazole were separated on TLC silica gel 60F254 plate using chloroform: acetone: glacial acetic acid (7.5: 2.5: 0.1, by volume) as mobile phase. The obtained bands were then scanned at 254 nm. The second method is a RP-HPLC method in which diiodohydroxyquinoline and metronidazole were separated on a reversed-phase C18 column using water : methanol (60 :40, V/V, PH=3.6 )as mobile phase at a flow rate of 0.7 mL.min-1 and UV detection at 220 nm. The mentioned methods were successfully used for determination of diiodohydroxyquinoline and metronidazole in pure form and in their pharmaceutical formulation. Keywords: TLC-spectrodensitometry, RP-HPLC, diiodohydroxyquinoline and metronidazole. INTRODUCTION (Argekaret al., 1996), GC (Wang et al., 2001), atomic absorption spectrometry (Nejem et al., 2008), iodometric Metronidazole (MTN) is 2-methyl-5-nitroimidazole-1- titration (Soliman, 1975) and non aqueous titration ethanol (Merck, 2006). It is a 5-nitroimidazole derivative (Kavarana, 1959; Paranjothy and Banerjee., 1973). with activity against anaerobic bacteria and protozoa. MTN is an amoebicide at whole sites of infection with Few methods have been mentioned for analysis of DIHQ Entamoeba histolytica.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services
    Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%).
    [Show full text]
  • Aloxiprine Tab 600Mg) Buffered Aspirine 60,000 02-08-00002 Acebutolol Tab 200Mg 470 02-08-00003 Acnil Cream
    SUPPLEMNTARY LIST OF MEDECINE No. ITEM NAME NORTH 02-08-00001 (Aloxiprine Tab 600mg) Buffered Aspirine 60,000 02-08-00002 Acebutolol Tab 200mg 470 02-08-00003 Acnil Cream. 6,400 02-08-00004 Acriflavin 0.1% + Cod.Liver Oil 10% Cream(Burn Cream.) 6,000 02-08-00005 Acriflavine Powder 50gm 100 02-08-00006 Acyclovir 5% Cream, 300 02-08-00007 Acyclovir Tab 200mg 13,000 02-08-00008 Al 110 Powder 12,000 02-08-00009 Alginic Acid 500mg + Mag.Trisilicate 25mg + Dried Al.Hydroxide Gel 100mg 200,000 +Sod.Bicarb.170mg Tab (Gaviscon) 02-08-00010 Alphacalcidol Caps 0.25mcg 1,000 02-08-00011 Alphacalcidol Caps 1mcg 1,000 02-08-00012 Aluminium Hydroxide Tab 475mg 400,000 02-08-00013 Aminophylline Supp.125mg 500 02-08-00014 Aminophylline Syr 50mg/5ml 460 02-08-00015 Amiodarone Inj 50mg/Ml, 3ml 100 02-08-00016 Amitriptyline Cap 75mg (S/R) 1,000 02-08-00017 Amitriptyline Tab 10mg 52,000 02-08-00018 Amnipaque 120 02-08-00019 Amoxycillin Cap 500mg 1,300,000 02-08-00020 Amphotericin Tab 100mg 3,000 02-08-00021 Angoivag Aerosol 3,000 02-08-00022 Antazoline 0.5% + Naphthazoline O.025% Eye Drops, 10ml 50,000 02-08-00023 Aprotinin Inj 20 000 U/Ml, 5ml 100 02-08-00024 Ascorbic Acid Tab 500mg 900,000 02-08-00025 Astemizol Syr 200 02-08-00026 Astemizol Tab 10 Mg ( Hismamol) 200,000 02-08-00027 Atropine Sulphate 0.5% Eye Drops, 5ml 700 02-08-00028 Auranofin Tab 3mg 500 02-08-00029 Azoline 0.5% + Naphthazoline O.025% Eye Drops, 10ml 45,000 02-08-00030 B-Complex Cap 100,000 02-08-00031 B-Complex Inj 150,000 02-08-00032 B-Complex Tab.
    [Show full text]
  • Australian Statistics on Medicines 1999–2000
    Commonwealth Department of Health and Ageing Australian Statistics on Medicines 1999–2000 © Commonwealth of Australia 2003 ISBN 0 642 82184 4 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Commonwealth available from AusInfo. Requests and inquiries concerning reproduction and rights should be addressed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra ACT 2601. Publications Approval Number: 3183 (PA7270) FOREWORD Comprehensive and valid statistics on use of medicines by Australians in the public domain should be accessible to all interested parties. From the first edition in 1992 until 1999 the Drug Utilisation SubCommittee (DUSC) produced the Australian Statistics on Medicines (ASM) for each calendar year to 1998. It is pleasing indeed to be able to present these again this year, with the inclusion of estimates for the years since the last edition. A continuous data set representing estimates of the aggregate community use (non public hospital) of prescription medicines in Australia is a key tool for the Australian Medicines Policy. The ASM presents dispensing data on most drugs marketed in Australia and is the only current source of data in Australia to cover all prescription medicines dispensed in the community. Drug utilisation data can assist the targeting and evaluation of quality use of medicines initiatives, and the evaluation of changes to the availability of medicines. It is also needed for pharmacosurveillance by regulatory and financing authorities and by the Pharmaceutical Industry. Publication of the Australian data also facilitates international comparisons of drug utilisation profiles and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Parasitic Infections (1 of 14)
    Parasitic Infections (1 of 14) 1 Patient presents w/ signs & symptoms suggestive of GI parasitic infection 2 DIAGNOSIS No ALTERNATIVE Is a GI parasitic infection DIAGNOSIS confi rmed? Yes Protozoal or helminthic infection? Protozoal Infection Helminthic Infection A Rehydration & nutrition B Prevention PHARMACOLOGICAL PHARMACOLOGICAL THERAPY FOR THERAPY FOR PROTOZOAL HELMINTHIC INFECTIONS INFECTIONS ©See page 3 MIMSSee page 3 B1 © MIMS 2019 Parasitic Infections (2 of 14) 1 SIGNS & SYMPTOMS OF GI PARASITIC INFECTIONS GI Symptoms • Abdominal pain, diarrhea, dysentery, fl atulence, malabsorption, symptoms of biliary obstruction Nonspecifi c Symptoms • Fever, malaise, fatigue, anorexia, sweating, wt loss, edema & pruritus • Some patients may be asymptomatic PARASITIC INFECTIONS PARASITIC 2 DIAGNOSIS Clinical History • Attempt to elicit a history of possible exposure, especially for helminthic infections, eg eating undercooked meat, source of drinking water, swimming in fresh water where certain parasites may be endemic • Knowledge of the geographic distribution of parasites is helpful in the diagnosis of patients Host Susceptibility Factors in GI Parasitic Infections • Nutritional status • Intercurrent disease • Pregnancy • Immunosuppressive drugs • Presence of a malignancy Physical Exam Findings • Pallor • Hepatomegaly • Ascites • Ileus • Rectal prolapse Lab Tests Microscopic Exam of Stools • Fundamental to the diagnosis of all GI infections - A minimum of 3 stool specimens, examined by trained personnel using a concentration & a permanent stain
    [Show full text]